메뉴 건너뛰기




Volumn 177, Issue 1, 2017, Pages 47-62

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management

Author keywords

[No Author keywords available]

Indexed keywords

BRODALUMAB; ETANERCEPT; INTERLEUKIN 17; IXEKIZUMAB; PLACEBO; SECUKINUMAB; USTEKINUMAB; IL17A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

EID: 85020111766     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15015     Document Type: Review
Times cited : (224)

References (51)
  • 1
    • 84904545875 scopus 로고    scopus 로고
    • Secukinumab in plaque psoriasis – results of two phase 3 trials
    • Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
    • (2014) N Engl J Med , vol.371 , pp. 326-338
    • Langley, R.G.1    Elewski, B.E.2    Lebwohl, M.3
  • 2
    • 84949096255 scopus 로고    scopus 로고
    • Interleukin 17-A inhibition in the treatment of psoriasis
    • Yiu ZZ, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev Clin Immunol 2016; 12:1–4.
    • (2016) Expert Rev Clin Immunol , vol.12 , pp. 1-4
    • Yiu, Z.Z.1    Griffiths, C.E.2
  • 3
    • 84922698975 scopus 로고    scopus 로고
    • IL-17 and infections
    • Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr 2014; 105 (Suppl.):34–40.
    • (2014) Actas Dermosifiliogr , vol.105 , pp. 34-40
    • Ling, Y.1    Puel, A.2
  • 4
    • 84939440636 scopus 로고    scopus 로고
    • To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis
    • Ahn CS, Dothard EH, Garner ML et al. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 2015; 73:420–8.
    • (2015) J Am Acad Dermatol , vol.73 , pp. 420-428
    • Ahn, C.S.1    Dothard, E.H.2    Garner, M.L.3
  • 5
    • 84963854339 scopus 로고    scopus 로고
    • Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors
    • Salt E, Wiggins AT, Rayens MK et al. Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors. Arthritis Rheumatol 2016; 68:597–603.
    • (2016) Arthritis Rheumatol , vol.68 , pp. 597-603
    • Salt, E.1    Wiggins, A.T.2    Rayens, M.K.3
  • 6
    • 79959210742 scopus 로고    scopus 로고
    • Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy
    • Ruhnke M, Rickerts V, Cornely OA et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011; 54:279–310.
    • (2011) Mycoses , vol.54 , pp. 279-310
    • Ruhnke, M.1    Rickerts, V.2    Cornely, O.A.3
  • 8
    • 84877800182 scopus 로고    scopus 로고
    • Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment
    • Picciani BLS, Michalski-Santos B, Carneiro S et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol 2013; 68:986–91.
    • (2013) J Am Acad Dermatol , vol.68 , pp. 986-991
    • Picciani, B.L.S.1    Michalski-Santos, B.2    Carneiro, S.3
  • 9
    • 84864359374 scopus 로고    scopus 로고
    • Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy
    • Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther 2012; 14:217.
    • (2012) Arthritis Res Ther , vol.14 , pp. 217
    • Huppler, A.R.1    Bishu, S.2    Gaffen, S.L.3
  • 10
    • 84939463415 scopus 로고    scopus 로고
    • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
    • Thaçi D, Blauvelt A, Reich K et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73:400–9.
    • (2015) J Am Acad Dermatol , vol.73 , pp. 400-409
    • Thaçi, D.1    Blauvelt, A.2    Reich, K.3
  • 11
    • 84925356093 scopus 로고    scopus 로고
    • Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
    • Papp K, Menter A, Strober B et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2015; 72:e1.
    • (2015) J Am Acad Dermatol , vol.72
    • Papp, K.1    Menter, A.2    Strober, B.3
  • 12
    • 84949759880 scopus 로고    scopus 로고
    • Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials
    • Gottlieb AB, Langley RG, Philipp S et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol 2015; 14:821–33.
    • (2015) J Drugs Dermatol , vol.14 , pp. 821-833
    • Gottlieb, A.B.1    Langley, R.G.2    Philipp, S.3
  • 13
    • 84915805860 scopus 로고    scopus 로고
    • Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
    • Ohtsuki M, Morita A, Abe M et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014; 41:1039–46.
    • (2014) J Dermatol , vol.41 , pp. 1039-1046
    • Ohtsuki, M.1    Morita, A.2    Abe, M.3
  • 14
    • 84969406048 scopus 로고    scopus 로고
    • Improvement in psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory with brodalumab treatment in patients with psoriatic arthritis
    • Mease PJ, Genovese MC, Mutebi A et al. Improvement in psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory with brodalumab treatment in patients with psoriatic arthritis. J Rheumatol 2016; 43:343–9.
    • (2016) J Rheumatol , vol.43 , pp. 343-349
    • Mease, P.J.1    Genovese, M.C.2    Mutebi, A.3
  • 15
    • 84988039700 scopus 로고    scopus 로고
    • A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
    • Papp KA, Reich K, Paul C et al. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175:273–86.
    • (2016) Br J Dermatol , vol.175 , pp. 273-286
    • Papp, K.A.1    Reich, K.2    Paul, C.3
  • 16
    • 84942876148 scopus 로고    scopus 로고
    • Phase 3 studies comparing brodalumab with ustekinumab in psoriasis
    • Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
    • (2015) N Engl J Med , vol.373 , pp. 1318-1328
    • Lebwohl, M.1    Strober, B.2    Menter, A.3
  • 17
    • 84937972700 scopus 로고    scopus 로고
    • Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)
    • Mrowietz U, Leonardi CL, Girolomoni G et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015; 73:e1.
    • (2015) J Am Acad Dermatol , vol.73
    • Mrowietz, U.1    Leonardi, C.L.2    Girolomoni, G.3
  • 18
    • 84937984975 scopus 로고    scopus 로고
    • Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
    • Thaçi D, Humeniuk J, Frambach Y et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol 2015; 173:777–87.
    • (2015) Br J Dermatol , vol.173 , pp. 777-787
    • Thaçi, D.1    Humeniuk, J.2    Frambach, Y.3
  • 19
    • 84929629144 scopus 로고    scopus 로고
    • Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
    • Paul C, Lacour J-P, Tedremets L et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015; 29:1082–90.
    • (2015) J Eur Acad Dermatol Venereol , vol.29 , pp. 1082-1090
    • Paul, C.1    Lacour, J.-P.2    Tedremets, L.3
  • 20
    • 84922933349 scopus 로고    scopus 로고
    • Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
    • Blauvelt A, Prinz JC, Gottlieb AB et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172:484–93.
    • (2015) Br J Dermatol , vol.172 , pp. 484-493
    • Blauvelt, A.1    Prinz, J.C.2    Gottlieb, A.B.3
  • 21
    • 84942891597 scopus 로고    scopus 로고
    • Secukinumab Inhibition of interleukin-17A in patients with psoriatic arthritis
    • Mease PJ, McInnes IB, Kirkham B et al. Secukinumab Inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015; 373:1329–39.
    • (2015) N Engl J Med , vol.373 , pp. 1329-1339
    • Mease, P.J.1    McInnes, I.B.2    Kirkham, B.3
  • 22
    • 84942198180 scopus 로고    scopus 로고
    • Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    • McInnes IB, Mease PJ, Kirkham B et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386:1137–46.
    • (2015) Lancet , vol.386 , pp. 1137-1146
    • McInnes, I.B.1    Mease, P.J.2    Kirkham, B.3
  • 23
    • 84873168729 scopus 로고    scopus 로고
    • Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study
    • Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168:402–11.
    • (2013) Br J Dermatol , vol.168 , pp. 402-411
    • Rich, P.1    Sigurgeirsson, B.2    Thaci, D.3
  • 24
    • 84977760286 scopus 로고    scopus 로고
    • Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis
    • van der Heijde D, Landewé RB, Mease PJ et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol 2016; 68:1914–21.
    • (2016) Arthritis Rheumatol , vol.68 , pp. 1914-1921
    • van der Heijde, D.1    Landewé, R.B.2    Mease, P.J.3
  • 25
    • 84985920039 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study
    • Imafuku S, Honma M, Okubo Y et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol 2016; 43:1011–7.
    • (2016) J Dermatol , vol.43 , pp. 1011-1017
    • Imafuku, S.1    Honma, M.2    Okubo, Y.3
  • 26
    • 84984999085 scopus 로고    scopus 로고
    • Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study
    • Kavanaugh A, McInnes IB, Mease PJ et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 2016; 43:1713–7.
    • (2016) J Rheumatol , vol.43 , pp. 1713-1717
    • Kavanaugh, A.1    McInnes, I.B.2    Mease, P.J.3
  • 27
    • 84891740105 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
    • McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73:349–56.
    • (2014) Ann Rheum Dis , vol.73 , pp. 349-356
    • McInnes, I.B.1    Sieper, J.2    Braun, J.3
  • 28
    • 84925226246 scopus 로고    scopus 로고
    • Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
    • Papp K, Leonardi C, Menter A et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014; 71:e3.
    • (2014) J Am Acad Dermatol , vol.71
    • Papp, K.1    Leonardi, C.2    Menter, A.3
  • 29
    • 84955327621 scopus 로고    scopus 로고
    • Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study
    • Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci 2015; 81:44–52.
    • (2015) J Dermatol Sci , vol.81 , pp. 44-52
    • Nakagawa, H.1    Niiro, H.2    Ootaki, K.3
  • 30
    • 84859017988 scopus 로고    scopus 로고
    • Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
    • Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181–9.
    • (2012) N Engl J Med , vol.366 , pp. 1181-1189
    • Papp, K.A.1    Leonardi, C.2    Menter, A.3
  • 31
    • 84902209516 scopus 로고    scopus 로고
    • Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis
    • Mease PJ, Genovese MC, Greenwald MW et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370:2295–306.
    • (2014) N Engl J Med , vol.370 , pp. 2295-2306
    • Mease, P.J.1    Genovese, M.C.2    Greenwald, M.W.3
  • 32
    • 84859073115 scopus 로고    scopus 로고
    • Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
    • Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190–9.
    • (2012) N Engl J Med , vol.366 , pp. 1190-1199
    • Leonardi, C.1    Matheson, R.2    Zachariae, C.3
  • 33
    • 84977071601 scopus 로고    scopus 로고
    • Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
    • Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345–56.
    • (2016) N Engl J Med , vol.375 , pp. 345-356
    • Gordon, K.B.1    Blauvelt, A.2    Papp, K.A.3
  • 34
    • 84919783193 scopus 로고    scopus 로고
    • A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
    • Gordon KB, Leonardi CL, Lebwohl M et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014; 71:1176–82.
    • (2014) J Am Acad Dermatol , vol.71 , pp. 1176-1182
    • Gordon, K.B.1    Leonardi, C.L.2    Lebwohl, M.3
  • 35
    • 84929630475 scopus 로고    scopus 로고
    • Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
    • Saeki H, Nakagawa H, Ishii T et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29:1148–55.
    • (2015) J Eur Acad Dermatol Venereol , vol.29 , pp. 1148-1155
    • Saeki, H.1    Nakagawa, H.2    Ishii, T.3
  • 36
    • 84940438565 scopus 로고    scopus 로고
    • Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
    • Langley RG, Rich P, Menter A et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2015; 29:1763–70.
    • (2015) J Eur Acad Dermatol Venereol , vol.29 , pp. 1763-1770
    • Langley, R.G.1    Rich, P.2    Menter, A.3
  • 37
    • 79960094057 scopus 로고    scopus 로고
    • STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis
    • van de Veerdonk FL, Plantinga TS, Hoischen A et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54–61.
    • (2011) N Engl J Med , vol.365 , pp. 54-61
    • van de Veerdonk, F.L.1    Plantinga, T.S.2    Hoischen, A.3
  • 38
    • 79961154447 scopus 로고    scopus 로고
    • Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
    • Liu L, Okada S, Kong X-F et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208:1635–48.
    • (2011) J Exp Med , vol.208 , pp. 1635-1648
    • Liu, L.1    Okada, S.2    Kong, X.-F.3
  • 39
    • 84937695151 scopus 로고    scopus 로고
    • IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans
    • Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol 2015; 195:780–8.
    • (2015) J Immunol , vol.195 , pp. 780-788
    • Conti, H.R.1    Gaffen, S.L.2
  • 40
    • 84876117810 scopus 로고    scopus 로고
    • C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways
    • Plato A, Willment JA, Brown GD. C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int Rev Immunol 2013; 32:134–56.
    • (2013) Int Rev Immunol , vol.32 , pp. 134-156
    • Plato, A.1    Willment, J.A.2    Brown, G.D.3
  • 41
    • 84941732206 scopus 로고    scopus 로고
    • Delinking CARD9 and IL-17: CARD9 protects against Candida tropicalis infection through a TNF-α-dependent, IL-17-independent mechanism
    • Whibley N, Jaycox JR, Reid D et al. Delinking CARD9 and IL-17: CARD9 protects against Candida tropicalis infection through a TNF-α-dependent, IL-17-independent mechanism. J Immunol 2015; 195:3781–92.
    • (2015) J Immunol , vol.195 , pp. 3781-3792
    • Whibley, N.1    Jaycox, J.R.2    Reid, D.3
  • 42
    • 68849084891 scopus 로고    scopus 로고
    • Structure and signalling in the IL-17 receptor family
    • Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9:556–67.
    • (2009) Nat Rev Immunol , vol.9 , pp. 556-567
    • Gaffen, S.L.1
  • 43
    • 84913595693 scopus 로고    scopus 로고
    • Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis
    • Taheri Sarvtin M, Shokohi T, Hajheydari Z et al. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol 2014; 53:e555–60.
    • (2014) Int J Dermatol , vol.53 , pp. e555-e560
    • Taheri Sarvtin, M.1    Shokohi, T.2    Hajheydari, Z.3
  • 44
    • 84979742694 scopus 로고    scopus 로고
    • A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis
    • Armstrong AW, Bukhalo M, Blauvelt A. A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol 2016; 17:329–36.
    • (2016) Am J Clin Dermatol , vol.17 , pp. 329-336
    • Armstrong, A.W.1    Bukhalo, M.2    Blauvelt, A.3
  • 45
    • 84938992082 scopus 로고    scopus 로고
    • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    • Griffiths CEM, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
    • (2015) Lancet , vol.386 , pp. 541-551
    • Griffiths, C.E.M.1    Reich, K.2    Lebwohl, M.3
  • 46
    • 84990238873 scopus 로고    scopus 로고
    • Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
    • Yamasaki K, Nakagawa H, Kubo Y et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol 2017; 176:741–51.
    • (2017) Br J Dermatol , vol.176 , pp. 741-751
    • Yamasaki, K.1    Nakagawa, H.2    Kubo, Y.3
  • 47
    • 84914811284 scopus 로고    scopus 로고
    • Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014
    • Chen SC, Sorrell TC, Chang CC et al. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J 2014; 44:1315–32.
    • (2014) Intern Med J , vol.44 , pp. 1315-1332
    • Chen, S.C.1    Sorrell, T.C.2    Chang, C.C.3
  • 49
    • 84900829814 scopus 로고    scopus 로고
    • Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp
    • Arendrup MC, Cuenca-Estrella M, Lass-Flörl CHW. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Update 2013; 16:81–95.
    • (2013) Drug Resist Update , vol.16 , pp. 81-95
    • Arendrup, M.C.1    Cuenca-Estrella, M.2    Lass-Flörl, C.H.W.3
  • 50
    • 84959876270 scopus 로고    scopus 로고
    • Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America
    • Pappas PG, Kauffman CA, Andes DR et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1–50.
    • (2016) Clin Infect Dis , vol.62 , pp. e1-50
    • Pappas, P.G.1    Kauffman, C.A.2    Andes, D.R.3
  • 51
    • 84867691302 scopus 로고    scopus 로고
    • ECSMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS
    • Lortholary O, Petrikkos G, Akova M et al. ECSMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 2012; 18(Suppl. 7):68–77.
    • (2012) Clin Microbiol Infect , vol.18 , pp. 68-77
    • Lortholary, O.1    Petrikkos, G.2    Akova, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.